Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-05-20
2008-05-20
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093600, C435S235100
Reexamination Certificate
active
07374752
ABSTRACT:
Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4490358 (1984-12-01), Greene et al.
patent: 5023252 (1991-06-01), Hsieh
patent: 5614403 (1997-03-01), Ramig et al.
patent: 5874531 (1999-02-01), Strominger et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6261555 (2001-07-01), Lee et al.
patent: 6344195 (2002-02-01), Lee et al.
patent: 6455038 (2002-09-01), Lee et al.
patent: 0453242 (1991-10-01), None
patent: 0514603 (1992-11-01), None
patent: 90/09441 (1990-08-01), None
patent: 90/11765 (1990-10-01), None
patent: 94/18992 (1994-09-01), None
patent: 97/16443 (1997-05-01), None
patent: 98/08541 (1998-03-01), None
patent: 99/08692 (1999-02-01), None
patent: 99/18799 (1999-04-01), None
Nibert et al. Infectious subvirion particle of reovirus type 3 Dearing exhibit a loss in infectivity and contain a cleaved sigma1 protein. Journal of Virology (1995), vol. 69 (8), p. 5057-5067.
Sherry et al. reovirus induction of and seinsitivity to beta interferon in cardiac myocyte cultures with induction of myocarditis and are determined by viral core proteins. Journal of Virology (1989) vol. 72 (2), pp. 4850-4856.
Hooper et al. Role of hte u1 protein in reovirus stability and capacity to cause chromium release from hosts. Journal of Virology (1996) vol. 70(1), pp. 459-467.
Roner et al. Identification of signals required for the insertion of heterologous genome segments into the reovirus genome. PNAS (1995) vol. 92, pp. 12362-12366.
Baer et al . Mutations inreovirus outer-capsid protein selected during persistent infections of L cells confer resistance to protease inhibitor E64. Journal of Virology (1997) vol. 71(7), pp. 4921-4928.
Fields et al. Genetic and molecular mechanisms of viral parhogenesis:implications for prevention and treatment. Nature (1982) vol. 300, pp. 19-23.
Andreansky, S.S. et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA93:11313-11318 (1996).
Armstrong et al., “Studies on Reovirus Receptors of L Cells: Virus Binding Characteristics and Comparison with Reovirus Receptors of Erythrocytes”,Virology138:37-48 (1984).
Aronheim et al., “Membrane Targeting of the Nucleotide Exchange Factor Sos is sufficient for Activating the Ras Signaling Pathway”,Cell78:949-961 (1994).
Barbacid, M., “rasGenes,”Annu. Rev. Biochem.56:779-827 (1987).
Berrozpe et al. “Comparative Analysis of Mutations in thep53and K-rasGenes in Pancreatic Cancer”,Int. J. Cancer58: 185-191 (1994).
Bischoff et al., “Activation of the Human P1/eIF-2α Protein Kinase by Individual Reovirus s-Class mRNAs: s1 mRNA is a Potent Activator Relative to s4mRNA”,Virology172:106-115 (1989).
Boviatsis, E.J. et al., “Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase,”Gene Therapy1:323-331 (1994).
Bryson, J.S. and Cox, D.C., “Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia,”Cancer Immunol. Immunother.26:132-138 (1988).
Bos, “rasOncogenes in Human Cancer: A Review”,Cancer Research49: 4682-4689 (1989).
Cahill, M.A., et al., “Signalling pathways: Jack of all cascades,”Current Biology, 6(1):16-19 (1996).
Chambers, R. et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA92:1411-1415 (1995).
Chandran, Kartik et al., “Protease Cleavage of Reovirus Capsid Protein μ1/μ1C is Blocked by Alkyl Sulfate Detergents, Yielding a New Type of Infectious Subvirion Particle,”Journal of Virology, vol. 72, No. 1, pp. 467-475 (1998).
Chaubert et all, “K-rasMutations and p53 Alterations in Neoplastic and Nonneoplastic Lesions Associated with Longstanding Ulcerative Colitis”,American Journal of Pathology144:767-775 (1994).
Cuff et al., “Enteric Reovirus Infection as a Probe to Study Immunotoxicity of the Gastrointestinal Tract”,Toxicological Sciences142:99-108 (1998).
Coffey, Matthew C. et al., “Reovirus Therapy of Tumors with Activated Ras Pathway,”Science(Washington D.C.), vol. 282, No. 5392, pp. 1332-1334 (1998).
Database Biosis Online!, Biosciences Information Service, Philadelphia, PA, US; 1996, Bollag Gideon et al., “Loss of NF1 Results in Activation of the Ras Signalling Pathway and Leads to Aberrant Growth in Haematopoietic Cells,”Nature Genetics, vol. 12, No. 2, pp. 144-148 (1996).
Der et al., “A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis”,Proc Natl. Acad. Sci. USA94:3279-3283 (1997).
Dudley et al., “A synthetic inhibitor of the mitogen-activated protein kinase cascade”,Proc. Natl. Acad. Sci. USA92:7686-7689 (1995).
Duncan, M.R. et al., “Differential Sensitivity of Normal and Transformed Human Cells to Reovirus Infection,”J. of Virol.28(2):444-449 (1978).
Duncan et al., “Conformational and functional Analysis of the C-Terminal Globular Head of the Reovirus Cell Attachment Protein”,Virology182: 810-9819 (1991).
Gale, Jr. et al., “Evidence that Hepatitis C Virus Resistance to Interferon is Mediated Through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein”Virology230:217-227 (1997).
Gentsch, J.R. and Pacitti, A.F., “Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3 Reovirus Attachment to Murine L Cells,” J. of Virol. 56 (2):356-364 (1985).
Hall-Jackson, C.A. et al., “Induction of Cell Death by Stimulation of Protein Kinase C in Human Epithelial Cells Expressing a MutantrasOncogene: A Potential Therapeutic Target,”British Journal of Cancer, vol. 78, No. 5, pp. 641-651 (1998).
Hashiro et al., “The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines”,Archives of Virology54(4):307-315 (1977).
He et al., “Suppression of the Phenotype of γ134.5-Herpes Simplex Virus 1: Failure of Activated RNA-Dependent Protein Kinase to Shut Off Protein Synthesis is Associated with a Deletion in the Domain of the α47 Gene”J. of Virol.71(8):6049-6054 (1997).
Helbing et al., “A Novel Candidate Tumor Suppressor,INGI, IS Involved in the Regulation of Apoptosis”,Cancer Research57:1255-1258, (1997).
Hershey, J.W.B., “Translation Control in Mammalian Cells,”Annu. Rev. Biochem. 60:717-755 (1991).
Hu et al., “2-Aminopurine Inhibits the Double-Stranded RNA-Dependent Protein Kinase Both In Vitro and In Vivo”,Journal of Interferon Research13: 323-328 (1993).
Janes et al., “Activation of the Ras signaling pathway in human breast cancer cells overexpressingerbB-2”,Oncogene9:2601-3608 (1994).
Kawagishi-Kobayashi et al., “Regulation of the Protein Kinase PKR by the Vaccinia Virus Pseudosubstrate Inhibitor K3L is Dependent on Residues Conserved Between the K3L Protein and the PKR Substrate 3IF2α”Mol. and Cell Biol. 17(7)
Coffey Matthew C.
Lee Patrick W. K.
Strong James
Fish & Richardson P.C.
Guzo David
Oncolytics Biotech Inc.
LandOfFree
Reovirus for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763334